SCHEMBL1966228

SCHEMBL1966228

CC(C)(C)OC(=O)N(Cc1ccc(C(F)(F)F)cc1)n1cccc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LSS P48449 1/20 0.40
MTOR P42345 1/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
NCOR2 Q9Y618 1/20 0.38
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
PYCR1 P32322 1/20 0.36
KCNH2 Q12809 1/20 0.36
MAOB P27338 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1966131 0.87 KDM1A (0.42) MEN1KMT2AHDAC3HDAC1HDAC2
SCHEMBL1966223 0.86 ALDH1A1 (0.42) MEN1KMT2AKDM4EALDH1A1MAOB
SCHEMBL1964950 0.85 AKT1 (0.46) MEN1KMT2AHDAC3HDAC1HDAC2
SCHEMBL1965400 0.84 GAA (0.40) MEN1KMT2ALSSPPARGPPARA
SCHEMBL1965931 0.83 L3MBTL1 (0.43) MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL1964559 0.80 LMNA (0.44) KDM4EALDH1A1MAOB
SCHEMBL1965415 0.79 GPR119 (0.36) HDAC3HDAC1HDAC2NCOR2KDM4E
SCHEMBL1965544 0.79 RIPK1 (0.47) MEN1KMT2AALDH1A1MAOBSMN1; SMN2
SCHEMBL1965084 0.79 CTSB (0.40) MEN1KMT2ALSSHDAC3HDAC1
SCHEMBL5018764 0.77 LSS (0.44) MEN1KMT2ALSSMTORPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 MEN1 3904/4885KMT2A 701/4885LSS 2313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.